Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19803653 | 1.00 | KCNH2 (0.38) | KCNH2SCN3ACALCRLTDP1LIPE | |
| SCHEMBL20835919 | 1.00 | KCNH2 (0.38) | KCNH2SCN3ACALCRLTDP1LIPE | |
| SCHEMBL20843433 | 1.00 | KCNH2 (0.38) | KCNH2SCN3ACALCRLTDP1LIPE | |
| SCHEMBL20835800 | 0.91 | KCNH2 (0.38) | KCNH2SCN3ATDP1LIPERIPK1 | |
| SCHEMBL20835798 | 0.91 | KCNH2 (0.38) | KCNH2SCN3ATDP1LIPERIPK1 | |
| SCHEMBL19803547 | 0.85 | RIPK1 (0.39) | KCNH2SCN3ATDP1LIPERIPK1 | |
| SCHEMBL20843379 | 0.85 | RIPK1 (0.39) | KCNH2SCN3ATDP1LIPERIPK1 | |
| SCHEMBL20835644 | 0.80 | CALCRL (0.39) | KCNH2SCN3ACALCRLTDP1RIPK1 | |
| SCHEMBL20843553 | 0.80 | CALCRL (0.39) | KCNH2SCN3ACALCRLTDP1RIPK1 | |
| SCHEMBL19803651 | 0.80 | CALCRL (0.39) | KCNH2SCN3ACALCRLTDP1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| CN-109476639-B | Pyrrolidine derivatives | 橘生药品工业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | KCNH2 292/4885SCN3A 742/4885CALCRL 1/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | KCNH2 292/4885SCN3A 742/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.